ClinicalTrials.gg
Sign In
Not yet recruitingNCT07807969AiiM OLEUpdated Sep 8, 2026

An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Phase 3 interventional study of Vonaprument in Geographic Atrophy, sponsored by Annexon, Inc.. Not yet recruiting at 7 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Annexon, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
605
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

02

Conditions studied

  • Geographic Atrophy

Browse trials for

03

In context

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 605 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.

Exclusion criteria

Exclusion Criteria:

  • Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
605 participants (estimated)

Study arms

  • Experimental
    Vonaprument

    Participants will receive vonaprument IVT injections every month for 24 months.

    Drug: Vonaprument

Interventions

  • DrugVonaprument

    Form: solution for injection; Route of Administration: IVT injection

    Also known as: ANX007

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events

    Time frame: Through Month 24

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jul 2029, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 8, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07807969
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Study Coordinator
Contact
clinicaltrials@annexonbio.com
650-822-5500
Clinical Trials
study director · Annexon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonaprument

Other studies in this condition

Geographic Atrophy →

Other studies from this sponsor

Annexon, Inc.

Start the discussion